EVEREST STUDY: Efficacy and Safety of Verteporfin Photodynamic Therapy in Combination with Ranibizumab or Alone Versus Ranibizumab Monotherapy in Patients with Symptomatic Macular Polypoidal Choroidal Vasculopathy
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Methods: In this multicenter, double-masked, primarily indocyanine green angiography–guided trial, 61 Asian patients were randomized to verteporfin PDT (standard fluence), ranibizumab 0.5 mg, or the combination. Patients were administered with verteporfin PDT/placebo and initiated with three consecutive monthly ranibizumab/sham injections starting Day 1, and re-treated (Months 3–5) as per predefined criteria. The primary endpoint was the proportion of patients with indocyanine green angiography–assessed complete regression of polyps at Month 6. Secondary endpoints included mean change in best-corrected visual acuity at Month 6 and safety. Results: At Month 6, verteporfin combined with ranibizumab or alone was superior to ranibizumab monotherapy in achieving complete polyp regression (77.8% and 71.4% vs. 28.6%; P < 0.01); mean change ± standard deviation in best-corrected visual acuity (letters) was 10.9 ± 10.9 (verteporfin PDT + ranibizumab), 7.5 ± 10.6 (verteporfin PDT), and 9.2 ± 12.4 (ranibizumab). There were no new safety findings with either drug used alone or in combination. Conclusion: Verteporfin PDT combined with ranibizumab 0.5 mg or alone was superior to ranibizumab monotherapy in achieving complete regression of polyps in this 6-month study in patients with symptomatic macular polypoidal choroidal vasculopathy. All treatments were well tolerated over 6 months. EVEREST, the first, multicenter, double-masked, primarily indocyanine green angiography–guided randomized controlled trial for symptomatic macular polypoidal choroidal vasculopathy, demonstrated superiority of verteporfin photodynamic therapy combined with ranibizumab or alone over ranibizumab monotherapy in achieving complete regression of polyps at Month 6. Best-corrected visual acuity improved in all treatment arms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the United Kingdom, ICGA is not available in all units and is usually reserved for cases presenting with clinical features suspicious of polypoidal choroidopathy (IPCV) or retinal angiomatous proliferation (RAP) or when response to anti-VEGF therapy is suboptimal.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“Some lesion types are thought to be less responsive than others to anti-VEGF therapy, for example, IPCV.”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“The EVEREST study suggested that combination therapy of IPCV with photodynamic therapy (PDT) and ranibizumab led to a better outcome than monotherapy with ranibizumab.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“However, an expanding or increased elevation in PED indicates activity that merits evaluation and treatment.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
Citations
Cites
Chung, S. E., Kang, S. W., Lee, J. H., & Kim, Y. T. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.012 · Cited by 580
Polypoidal Choroidal Vasculopathy: Incidence, Demographic Features, and Clinical Characteristics
Sho, K. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.10.1392 · Cited by 439 · cited 1×
“Moreover, the incidence of sub-RPE hemorrhage or subretinal hemorrhage in patients with PCV is high (30%–64%).(3,9) In a study of the natural history of patients with PCV, Uyama et al(6) reported that half of the study eyes had hemorrhagic episodes, recurrent leakage, or severe RPE atrophy after a long follow-up perio…”
BackgroundThe Expanding Clinical Spectrum of Idiopathic Polypoidal Choroidal Vasculopathy
Yannuzzi, L. A. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100150480005 · Cited by 436 · cited 3×
“It may be associated with a branching vascular network (BVN) and clinically visible orange-red subretinal nodule(s).(1) Polypoidal choroidal vasculopathy is prevalent in 10% to 54% of the Asian patients and in 8% to 12% of white patients with presumed exudative age-related macular degeneration (AMD).”
BackgroundPolypoidal choroidal vasculopathy: natural history
Uyama, M., Wada, M., Nagai, Y., Matsubara, T., Matsunaga, H., Fukushima, I., Takahashi, K., & Matsumura, M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01404-6 · Cited by 402 · cited 3×
“In PCV, the polypoidal lesions originate from the inner choroidal vasculature and can progress beneath the RPE.(1,6,7) The presence of orange-red nodule–like structures beneath the RPE associated with an adjacent serous pigment epithelial detachment or overlying neurosensory detachment, subretinal hemorrhage, and lipi…”
BackgroundTong, J.-P., Chan, W.-M., Liu, D. T. L., Lai, T. Y. Y., Choy, K.-W., Pang, C.-P., & Lam, D. S. C. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.10.012 · Cited by 385 · cited 1×
“The increased expression of VEGF in the aqueous humor of eyes with PCV provides a biologic rationale for treatment with anti-VEGF agents.(19) Limited data from case series with bevacizumab monotherapy have shown that treatment may reduce leakage associated with PCV but is ineffective for complete regression of the pol…”
BackgroundSelf-citationPhotodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy
Chan, W.-M., Lam, D. S. C., Lai, T. Y. Y., Liu, D. T. L., Li, K. K. W., Yao, Y., & Wong, T.-H. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.12.056 · Cited by 283
Self-citation(2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(03)00223-x · Cited by 274 · cited 1×
“For CNV secondary to AMD, the Verteporfin In Photodynamic Therapy and the Treatment of AMD with Photodynamic Therapy study has demonstrated that there was gradual visual deterioration or no visual improvement with high re-treatment rate at 6 months for treated patients after verteporfin PDT administration.(25) This tr…”
ResultEfficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy
Gomi, F., Sawa, M., Sakaguchi, H., Tsujikawa, M., Oshima, Y., Kamei, M., & Tano, Y. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.122283 · Cited by 242 · cited 1×
“These findings are consistent with those reported earlier with other anti-VEGF therapies.(20,21)”
ResultGomi, F., Ohji, M., Sayanagi, K., Sawa, M., Sakaguchi, H., Oshima, Y., Ikuno, Y., & Tano, Y. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.02.031 · Cited by 239
The origins of polypoidal choroidal vasculopathy
Yuzawa, M. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2004.049296 · Cited by 198 · cited 4×
“Use of dynamic confocal scanning laser ophthalmoscope–ICGA may assist in further elucidating the BVN, from which these focal evaginating nodules arise, enabling clearer definition and differentiation from exudative AMD because of CNV.(7) Based on ICGA findings, PCV is defined as the presence of single or multiple foca…”
BackgroundInfluential
Cited by
Age-related macular degeneration
Fleckenstein, M., Keenan, T. D. L., Guymer, R. H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C. C., Wong, W. T., & Chew, E. Y. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00265-2 · Cited by 978
Optical coherence tomography based angiography [Invited]
Chen, C.-L., & Wang, R. K. (2017) · Biomedical Optics Express · doi:10.1364/boe.8.001056 · Cited by 415
Polypoidal Choroidal Vasculopathy
Cheung, C. M. G., Lai, T. Y. Y., Ruamviboonsuk, P., Chen, S.-J., Chen, Y., Freund, K. B., Gomi, F., Koh, A. H., Lee, W.-K., & Wong, T. Y. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.019 · Cited by 396
Self-citationMettu, P. S., Allingham, M. J., & Cousins, S. W. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100906 · Cited by 370
Defining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355
Age-Related Macular Degeneration Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.024 · Cited by 349
Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians
Wong, C. W., Yanagi, Y., Lee, W.-K., Ogura, Y., Yeo, I., Wong, T. Y., & Cheung, C. M. G. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.002 · Cited by 346
Self-citationLaíns, I., Wang, J. C., Cui, Y., Katz, R., Vingopoulos, F., Staurenghi, G., Vavvas, D. G., Miller, J. W., & Miller, J. B. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100951 · Cited by 324
Koh, A., Lai, T. Y. Y., Takahashi, K., Wong, T. Y., Chen, L.-J., Ruamviboonsuk, P., Tan, C. S., Feller, C., Margaron, P., Lim, T. H., et al. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.4030 · Cited by 301
Self-citationLee, W. K., Iida, T., Ogura, Y., Chen, S.-J., Wong, T. Y., Mitchell, P., Cheung, G. C. M., Zhang, Z., Leal, S., Ishibashi, T., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.1804 · Cited by 276
Self-citationPOLYPOIDAL CHOROIDAL VASCULOPATHY: Evidence-Based Guidelines for Clinical Diagnosis and Treatment
Koh, A. H. C., Chen, L.-J., Chen, S.-J., Chen, Y., Giridhar, A., Iida, T., Kim, H., Lai, T. Y. Y., Lee, W. K., Li, X., et al. (2013) · Retina · doi:10.1097/iae.0b013e3182852446 · Cited by 265
Self-citationAnti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options
Wallsh, J. O., & Gallemore, R. P. (2021) · Cells · doi:10.3390/cells10051049 · Cited by 166
“Tozer et al. combined half-fluence PDT (defined as laser applied at 300 mW, 25 J, 83 s) with IVB in 26 eyes.”
BackgroundInfluentialLim, T. H., Lai, T. Y. Y., Takahashi, K., Wong, T. Y., Chen, L.-J., Ruamviboonsuk, P., Tan, C. S., Lee, W. K., Cheung, C. M. G., Ngah, N. F., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2443 · Cited by 166
Self-citationOishi, A., Kojima, H., Mandai, M., Honda, S., Matsuoka, T., Oh, H., Kita, M., Nagai, T., Fujihara, M., Bessho, N., et al. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.024 · Cited by 150
Tan, C. S., Ngo, W. K., Chen, J. P., Tan, N., & Lim, T. H. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305674 · Cited by 142
Self-citationAnti–Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease
Campochiaro, P. A., Aiello, L. P., & Rosenfeld, P. J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.04.056 · Cited by 151
Wide-field optical coherence tomography based microangiography for retinal imaging
Zhang, Q., Lee, C. S., Chao, J. R., Chen, C., Zhang, T., Sharma, U., Zhang, A., Liu, J., Rezaei, K. A., Pepple, K. L., et al. (2016) · Scientific Reports · doi:10.1038/srep22017 · Cited by 133
One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
Yamamoto, A., Okada, A. A., Kano, M., Koizumi, H., Saito, M., Maruko, I., Sekiryu, T., & Iida, T. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.024 · Cited by 129
Pachychoroid disease: review and update
Cheung, C. M. G., Dansingani, K. K., Koizumi, H., Lai, T. Y. Y., Sivaprasad, S., Boon, C. J. F., van Dijk, E. H. C., Chhablani, J. K., Lee, W. K., & Freund, K. B. (2024) · Eye · doi:10.1038/s41433-024-03253-4 · Cited by 138
“Closure of the aneurysmal lesions with thermal laser or subsequently with PDT has been widely used [121].”
Self-citationKuroda, Y., Yamashiro, K., Miyake, M., Yoshikawa, M., Nakanishi, H., Oishi, A., Tamura, H., Ooto, S., Tsujikawa, A., & Yoshimura, N. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.053 · Cited by 124
“It was also reported that PDT was superior to ranibizumab for polyp regression.(38) Photodynamic therapy would be still an optional therapy for PCV even in the era of anti-VEGF treatment.”
Gomi, F., Oshima, Y., Mori, R., Kano, M., Saito, M., Yamashita, A., Iwata, E., & Maruko, R. (2015) · Retina · doi:10.1097/iae.0000000000000526 · Cited by 119
“The EVEREST study was a prospective randomized study with three treatment arms, that is, PDT combined with ranibizumab or alone versus ranibizumab monotherapy.(25) The study reported the superiority of PDT combined with ranibizumab or alone compared with ranibizumab monotherapy in achieving complete regression of poly…”
MethodPhotodynamic therapy: current role in the treatment of chorioretinal conditions
Newman, D. K. (2016) · Eye · doi:10.1038/eye.2015.251 · Cited by 124
Photodynamic therapy for polypoidal choroidal vasculopathy
Nowak-Sliwinska, P. M., van den Bergh, H., Sickenberg, M., & Koh, A. H. C. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.09.003 · Cited by 113
“PDT has consequently been used very successfully in treating PCV (Koh et al., 2012).”
InfluentialSelf-citationWong, T. Y., Ogura, Y., Lee, W. K., Iida, T., Chen, S., Mitchell, P., Cheung, C. M. G., Zhang, Z., Leal, S., & Ishibashi, T. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.02.027 · Cited by 110
Self-citationPolypoidal Choroidal Vasculopathy in Asians
Wong, C. W., Wong, T. Y., & Cheung, C. M. G. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4050782 · Cited by 110
“The EVEREST study [114] was the first randomized controlled trial evaluating standard fluence PDT with or without ranibizumab 0.”
BackgroundMethodInfluentialBorooah, S., Sim, P. Y., Phatak, S., Moraes, G., Wu, C. Y., Cheung, C. M. G., Pal, B., & Bujarborua, D. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14683 · Cited by 107
Lee, C. S., Woo, S. J., Kim, Y., Hwang, D. D.-J., Kang, H. M., Kim, H., & Lee, S. C. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.043 · Cited by 97
“orange subretinal nodule in color fundus photographs, and association with massive submacular hemorrhage.(8)”
BackgroundSelf-citationClinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care
Sirks, M. J., van Dijk, E. H. C., Rosenberg, N., Hollak, C. E. M., Aslanis, S., Cheung, C. M. G., Chowers, I., Eandi, C. M., Freund, K. B., Holz, F. G., et al. (2022) · Acta Ophthalmologica · doi:10.1111/aos.15148 · Cited by 94
ElSheikh, R. H., Chauhan, M. Z., & Sallam, A. B. (2022) · Biomolecules · doi:10.3390/biom12111629 · Cited by 98
COSCAS, G. J., Lupidi, M., Coscas, F., Benjelloun, F., Zerbib, J., Dirani, A., Semoun, O., & Souied, E. H. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-16236 · Cited by 89
Serous business: Delineating the broad spectrum of diseases with subretinal fluid in the macula
van Dijk, E. H. C., & Boon, C. J. F. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100955 · Cited by 96
Hatz, K. B., & Prünte, C. F. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303444 · Cited by 87
Lipécz, Á., Miller, L. R., Kovács, I., Czakó, C. N., Csípő, T., Baffi, J., Csiszár, A., Tarantini, S., Ungvari, Z. I., Yabluchanskiy, A., et al. (2019) · GeroScience · doi:10.1007/s11357-019-00138-3 · Cited by 93
Matsumoto, H., Hoshino, J., Mukai, R., Nakamura, K., & Akiyama, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-86014-7 · Cited by 84
Polypoidal Choroidal Vasculopathy: Clinical Features and Genetic Predisposition
Honda, S., Matsumiya, W., & Negi, A. (2013) · Ophthalmologica · doi:10.1159/000355488 · Cited by 82
Gianniou, C., Dirani, A., Jang, L., & Mantel, I. (2015) · Retina · doi:10.1097/iae.0000000000000465 · Cited by 81
Tan, C. S., Ngo, W. K., Lim, L. W., & Lim, T. H. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305059 · Cited by 77
Self-citationPachychoroid: current concepts on clinical features and pathogenesis
Castro-Navarro, V., Béhar‐Cohen, F., Chang, W., Joussen, A. M., Lai, T. Y. Y., Navarro, R., Pearce, I., Yanagi, Y., & Okada, A. A. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04940-0 · Cited by 76
“In 2012, the EVEREST study [49] proposed several diagnostic criteria based on ICGA imaging.”
MethodSelf-citationAdvances in swept-source optical coherence tomography and optical coherence tomography angiography
Zheng, F., Deng, X., Zhang, Q., He, J., Ye, P., Liu, S., Li, P., Zhou, J. Y., & Fang, X. (2022) · Advances in Ophthalmology Practice and Research · doi:10.1016/j.aopr.2022.10.005 · Cited by 76
THREE-YEAR RESULTS OF POLYPOIDAL CHOROIDAL VASCULOPATHY TREATED WITH PHOTODYNAMIC THERAPY
Wong, C. W., Cheung, C. M. G., Mathur, R., Li, X., Chan, C. M., Yeo, I. Y. S., Wong, E. Y., Lee, S. Y., Wong, D., & Wong, T. Y. (2015) · Retina · doi:10.1097/iae.0000000000000499 · Cited by 75
“6%).(20,21) Although it remains unclear whether this angiographic endpoint translates into a significant difference in visual acuity, PDT remains”
BackgroundBo, Q., Yan, Q., Shen, M., Song, M., Sun, M., Yu, Y., Rosenfeld, P. J., Wang, F., & Sun, X. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.0449 · Cited by 79
Chang, Y.-C., & Cheng, C. (2019) · Retina · doi:10.1097/iae.0000000000002583 · Cited by 77
Oishi, A., Miyamoto, N., Mandai, M., Honda, S., Matsuoka, T., Oh, H., Kita, M., Nagai, T., Bessho, N., Uenishi, M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.12.037 · Cited by 74
Morimoto, M., Matsumoto, H., Mimura, K., & Akiyama, H. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3718-6 · Cited by 76
Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy
Cho, H. J., Kim, K. M., Kim, H. S., Han, J. I., Kim, C. G., Lee, T. G., & Kim, J. W. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.02.019 · Cited by 76
“However, therewas no significant difference, in terms of visual outcome, between the anti-VEGF monotherapy group and the anti-VEGF combined with PDT group.(5,8) Moreover, severe vision loss due to extensive subretinal hemorrhage is not uncommon after PDT; one study found, for example, that complications such as subret…”
BackgroundMethodSelf-citationCho, J. H., Ryoo, N.-K., Cho, K. H., Park, S. J., Park, K. H., & Woo, S. J. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.06.014 · Cited by 73
“These results are compatible with previous reports that verteporfin combined with anti-VEGF therapy is superior to other treatment methods.(6) However, the interpretation of the association betweenmassive SMH and treatment requires caution because this study was not designed for scheduled treatment and could be biased…”
ResultClinical Characteristics and Current Treatment of Age-Related Macular Degeneration
Yonekawa, Y., & Kim, I. K. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017178 · Cited by 73
“Combining PDTwith anti-VEGF agents appears to be an effective approach (Kim and Yu 2011; Koh et al. 2012; Lee et al. 2012b; Tomita et al. 2012).”
BackgroundMethodInfluentialIntravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders
Hang, A., Feldman, S., Amin, A., Ochoa, J. R., & Park, S. S. (2023) · Pharmaceuticals · doi:10.3390/ph16081140 · Cited by 85
“Abbreviations AMD Age-related macular degeneration Anti-VEGF Drugs that inhibit vascular endothelial growth factor BRVO Branch retinal vein occlusion CRVO Central retinal vein occlusion DARPins Designed ankyrin repeat proteins DME diabetic macular edema DR Diabetic retinopathy EG-VEGF Endocrine gland-derived vascular…”
BackgroundInfluentialCho, H. J., Kim, H. S., Jang, Y. S., Han, J. I., Lew, Y. J., Lee, T. G., Kim, C. G., & Kim, J. W. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.07.001 · Cited by 71
Self-citationCheung, C. M. G., Yanagi, Y., Akïba, M., Tan, A. C. S., Mathur, R., Chan, C. M., Yeo, I. Y. S., & Wong, T. Y. (2018) · Retina · doi:10.1097/iae.0000000000002228 · Cited by 71
Polypoidal choroidal vasculopathy: an update on therapeutic approaches.
Wong, R. L. M., & Lai, T. Y. Y. (2013) · Europe PMC (PubMed Central) · Cited by 67
Self-citationSystemic Vascular Safety of Ranibizumab for Age-Related Macular Degeneration
Ueta, T., Noda, Y., Toyama, T., Yamaguchi, T., & Amano, S. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.022 · Cited by 70
Cheung, C. M. G., Grewal, D. S., Teo, K. Y. C., Gan, A. T. L., Mohla, A., Chakravarthy, U., Wong, T. Y., & Jaffe, G. J. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.06.002 · Cited by 64
Cheung, C. M. G., Yang, E., Lee, W. K., Lee, G. K. Y., Mathur, R., Cheng, J., Wong, D., Wong, T. Y., & Lai, T. Y. Y. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-2933-2 · Cited by 64
Self-citationKimura, S., Morizane, Y., Hosokawa, M. M., Shiode, Y., Kawata, T., Doi, S., Matoba, R., Hosogi, M., Fujiwara, A., Inoue, Y., et al. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.12.020 · Cited by 64
Xu, Y., Yan, K., Kim, J., Wang, X., Li, C., Su, L., Yu, S., Xu, X., & Feng, D. D. (2017) · Biomedical Optics Express · doi:10.1364/boe.8.004061 · Cited by 61
Yanagi, Y., Ting, D. S. W., Ng, W. Y., Lee, S. Y., Mathur, R., Chan, C. M., Yeo, I. Y. S., Wong, T. Y., & Cheung, C. M. G. (2017) · Retina · doi:10.1097/iae.0000000000001758 · Cited by 61
A Perspective on the Nature and Frequency of Pigment Epithelial Detachments
Tan, A. C. S., Simhaee, D., Balaratnasingam, C., Dansingani, K. K., & Yannuzzi, L. A. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.09.004 · Cited by 60
Matsumoto, H., Hoshino, J., Mukai, R., Nakamura, K., & Akiyama, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-10578-1 · Cited by 59
Cheung, C. M. G., Li, X., Mathur, R., Lee, S. Y., Chan, C. M., Yeo, I. Y. S., Loh, B. K., Williams, R. E., Wong, E. Y., Wong, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101057 · Cited by 60
Broadhead, G., Hong, T., & Chang, A. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12463 · Cited by 61
Cheung, C. M. G., Yanagi, Y., Mohla, A., Lee, S. Y., Mathur, R., Chan, C. M., Yeo, I. Y. S., & Wong, T. Y. (2016) · Retina · doi:10.1097/iae.0000000000001391 · Cited by 57
Matsumoto, H., Hoshino, J., Nakamura, K., Nagashima, T., & Akiyama, H. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06116-y · Cited by 57
“…goal when treating PCV. Previous studies showed that the rate of complete regression of polypoidal lesions after loading phase treatment with 3 monthly injections of an anti-VEGF agent was 23–33% for ranibizumab [23–25], 42–57% for aflibercept [22, 26–28], and 77–93% for brolucizumab [28–32].”
BackgroundKim, J., Lee, S. C., Kwon, K. Y., Lee, J. H., Koh, H. J., Byeon, S. H., Kim, S. S., Kim, M., & Lee, C. S. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-3221-x · Cited by 53
Evolving treatment paradigms for PCV
Fenner, B. J., Cheung, C. M. G., Sim, S. S., Lee, W. K., Staurenghi, G., Lai, T. Y. Y., Ruamviboonsuk, P., Kokame, G. T., Yanagi, Y., & Teo, K. Y. C. (2021) · Eye · doi:10.1038/s41433-021-01688-7 · Cited by 57
Self-citationAge-Related Macular Degeneration Preferred Practice Pattern®
Vemulakonda, G. A., Bailey, S. T., Kim, S. J., Kovach, J. L., Lim, J. I., Ying, G., & Flaxel, C. J. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2024.12.018 · Cited by 64
Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration
Frampton, J. E. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0077-9 · Cited by 54
Yadav, S., Parry, D., Beare, N. A. V., & Pearce, I. A. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-310074 · Cited by 51
Polypoidal choroidal vasculopathy: Pearls in diagnosis and management
Anantharaman, G., Sheth, J. U., Bhende, M. P., Narayanan, R., Natarajan, S., Rajendran, A., Manayath, G. J., Sen, P., Biswas, R. K., BANKER, A. S., et al. (2018) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1136_17 · Cited by 51
Fukuda, Y., Sakurada, Y., Matsubara, M., Hasebe, Y., Sugiyama, A., Kikushima, W., & Kashiwagi, K. (2021) · Biomedicines · doi:10.3390/biomedicines9091164 · Cited by 51
Ting, D. S. W., Cheung, C. M. G., Lim, L. S., & Yeo, I. Y. (2015) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12580 · Cited by 50
Wang, W., He, M., & Zhang, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110667 · Cited by 54
Five-Year Follow-up Results of Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
Kang, H. M., Kim, Y. M., & Koh, H. J. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.09.020 · Cited by 50
Li, Y., Busoy, J. M. F., Zaman, B. A. A., Tan, Q. S. W., Tan, G. S. W., Barathi, V. A., Cheung, N., Wei, J., Hunziker, W., Hong, W., et al. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.05.027 · Cited by 52
Lee, J. H., & Lee, W. K. (2015) · Retina · doi:10.1097/iae.0000000000000809 · Cited by 50
“network with polypoidal vascular dilations at the lesion borders, and polyps were defined as focal nodular areas of hyperfluorescence that appear within the first 6 minutes on ICGA in the EVEREST study.(28) Based on the current definition of PCV, Type 1 neovascularization in our series cannot be classified as PCV.”
BackgroundSelf-citationSaito, M., Kano, M., Itagaki, K., Oguchi, Y., & Sekiryu, T. (2014) · Retina · doi:10.1097/iae.0000000000000236 · Cited by 51
“6%) in patients with PCV with 6 months of follow-up.(34) Hikichi et al(21) also reported that polypoidal lesions resolved in 13 of 50 eyes (26%) treated with 3 consecutive monthly intravitreal injections of ranibizumab.”
BackgroundThe Royal College of Ophthalmologists Guidelines on AMD: Executive Summary
AMD Guidelines Group, Chakravarthy, U., & Williams, M. (2013) · Eye · doi:10.1038/eye.2013.233 · Cited by 47
Maruko, I., Ogasawara, M., Yamamoto, A., Itagaki, K., Hasegawa, T., Arakawa, H., Nakayama, M., Koizumi, H., Okada, A. A., Sekiryu, T., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.03.010 · Cited by 48
Kokame, G. T., Yeung, L., Teramoto, K., Lai, J. C., & Wee, R. (2013) · Ophthalmologica · doi:10.1159/000354072 · Cited by 46
Kitagawa, Y., Shimada, H., Mori, R., Tanaka, K., & Yuzawa, M. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.035 · Cited by 48
“Furthermore, this prospective study was designed to investigate submacular hemorrhage in both exudative AMD and PCV, but only 1 of 20 eyes enrolled had AMD.”
BackgroundInfluentialPolypoidal Choroidal Vasculopathy: An Update on Diagnosis and Treatment
Sen, P., Manayath, G. J., Shroff, D., Salloju, V., & Dhar, P. (2023) · Clinical ophthalmology · doi:10.2147/opth.s385827 · Cited by 45
“4 (ranibizumab).(40) The EVEREST II study reported a 34.”
InfluentialParikh, R., Pirakitikulr, N., Chhablani, J. K., Sakurada, Y., Singh, R. P., & Modi, Y. S. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.08.002 · Cited by 47
An update on the pharmacotherapy of neovascular age-related macular degeneration
Freund, K. B., Mrejen, S., & Gallego-Pinazo, R. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.787410 · Cited by 44
“The rationale for combined therapy in PCV is that the addition of PDT to ranibizumab alone results in a higher rate of polyp closure.”
BackgroundMethodInfluentialEFFICACY OF INTRAVITREAL INJECTION OF CONBERCEPT IN POLYPOIDAL CHOROIDAL VASCULOPATHY
Qu, J., Cheng, Y. H., Li, X., Yu, L., & Xiao, K. (2015) · Retina · doi:10.1097/iae.0000000000000875 · Cited by 44
Chaikitmongkol, V., Cheung, C. M. G., Koizumi, H., Govindahar, V., Chhablani, J. K., & Lai, T. Y. Y. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/01.apo.0000656992.00746.48 · Cited by 44
“The diagnosis of PCV was based on the presence of focal subretinal hyperfluorescence on confocal ICGA within the first 6 minutes plus 1 of the following criteria: nodular appearance of polyp(s) on stereoscopic examination, hypofluorescent halo around nodule(s), presence of a branching vascular network, pulsation of po…”
MethodSelf-citationLee, J. E., Shin, J. P., Kim, H. W., Chang, W., Kim, Y. C., Lee, S. J., Chung, I. Y., Lee, J. E., VAULT study group, Lee, J. E., et al. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3489-5 · Cited by 45
Self-citationREPAIR MECHANISM OF RETINAL PIGMENT EPITHELIAL TEARS IN AGE-RELATED MACULAR DEGENERATION
Mukai, R., Sato, T., & Kishi, S. (2014) · Retina · doi:10.1097/iae.0000000000000337 · Cited by 42
Kikushima, W., Sakurada, Y., Sugiyama, A., Tanabe, N., Kume, A., & Iijima, H. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3467-y · Cited by 43
Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration
Zhang, X., & Lai, T. Y. Y. (2018) · BioMed Research International · doi:10.1155/2018/9640131 · Cited by 50
“The complete regression rate of polyps is also significantly higher than in the combination group compared with the ranibizumab monotherapy group, suggesting that initially combined therapy can be considered as the first-line treatment strategy for PCV [76].”
ResultSelf-citationNguyen, Q. D., Agarwal, A. K., Rhoades, W. R., Hanout, M., Soliman, M. K., Sarwar, S., Sadiq, M. A., Sepah, Y. J., & Diana, V. (2015) · Clinical ophthalmology · doi:10.2147/opth.s74959 · Cited by 50
“87 However, results of the EVEREST study 47 and few uncontrolled studies 88,89 Powered by TCPDF (www.tcpdf.org) suggest that combination with PDT may lead to requirement of less frequent anti-VEGF injections.”
Yoshida, Y., Kohno, T., Yamamoto, M., Yoneda, T., Iwami, H., & Shiraki, K. (2013) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-013-0234-z · Cited by 39
“The EVEREST study examined the efficacy of SF-PDT and IVR combination therapy in PCV patients [23].”
MethodCho, H. J., Koh, K., Kim, H. S., Lee, T. G., Kim, C. G., & Kim, J. W. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.04.029 · Cited by 41
Self-citationPachychoroid disease spectrum: review article
Mazzeo, T. J. M. M., Leber, H. M., Silva, A. G., Freire, R. C. M., Barbosa, G. C. S., Criado, G. G., Jacob, G. A. V., Machado, C. G., & Gomes, A. M. V. (2021) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05450-3 · Cited by 41
Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study
Koizumi, H., Kano, M., Yamamoto, A., Saito, M., Maruko, I., Sekiryu, T., Okada, A. A., & Iida, T. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-306432 · Cited by 40
Tuuminen, R., Uusitalo‐Järvinen, H., Aaltonen, V., Hautala, N. M., Kaipiainen, S., Laitamäki, N., Ollila, M., Rantanen, J., Välimäki, S., Sipilä, R., et al. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13501 · Cited by 50
“When combined, PDT reduces the need for intravitreal anti-VEGF injections (Koh et al. 2012).”
BackgroundCho, J. H., Park, Y. J., Cho, S. C., Ryoo, N.-K., Cho, K. H., Park, S. J., Park, K. H., & Woo, S. J. (2018) · Retina · doi:10.1097/iae.0000000000002384 · Cited by 40
Cheung, C. M. G., Yeo, I. Y. S., Li, X., Mathur, R., Lee, S. Y., Chan, C. M., Wong, D., & Wong, T. Y. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.08.002 · Cited by 44
Ong, F. S.-C., Kuo, J. Z.-C., Wu, W., Cheng, C., Blackwell, W.-L. B., Taylor, B. L., Grody, W. W., Rotter, J. I., Lai, C., & Wong, T. Y. (2013) · Journal of Personalized Medicine · doi:10.3390/jpm3010040 · Cited by 40
“respond as well to anti-VEGF therapies as compared to PDT [65], and combination therapy with PDT and ranibizumab was associated with a more favorable outcome compared to ranibizumab monotherapy [66,67].”
ResultPolypoidal choroidal vasculopathy: An update on current management and review of literature
Khetan, V., & Palkar, A. H. (2019) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo_35_18 · Cited by 41
Matsumoto, H., Mukai, R., Kikuchi, Y. S., Morimoto, M., & Akiyama, H. (2020) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-020-00722-7 · Cited by 40
Metadata
- Authors
- Koh, A., Lee, W. K., Chen, L.-J., Chen, S.-J., Hashad, Y., Kim, H., Lai, T. Y., Pilz, S., Ruamviboonsuk, P., Tokaji, E., Weisberger, A., & Lim, T. H.
- Affiliations
- Eye & Retina Surgeons (SG)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Mackay Memorial Hospital (TW)
- Taipei Veterans General Hospital (TW)
- National Yang Ming University (TW)
- Corresponding author
- Koh, Adrian
- Hashad, Yehia
- Weisberger, Annemarie
- ORCID
- Venue
- Retina
- Published
- 2012-09
- Volume
- 32
- Issue
- 8
- Pages
- 1453-1464
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1976433015
- Cited by
- 587
- References
- 30
- Citations by year
- 2026: 21 · 2025: 39 · 2024: 32 · 2023: 20 · 2022: 31 · 2021: 54 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 63 · 2016: 52 · 2015: 51 · 2014: 39 · 2013: 41 · 2012: 8
- FWCI
- 41.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Retina (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Keywords
- verteporfin photodynamic therapy, ranibizumab, combination therapy, polyp regression, best-corrected visual acuity, anti-VEGF therapy, EVEREST trial
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Choroid, Combined Modality Therapy, Double-Blind Method, Coloring Agents, Female, Fluorescein Angiography, Humans, Indocyanine Green, Male, Middle Aged, Photochemotherapy, Polyps, Porphyrins, Visual Acuity, Choroid Diseases, Treatment Outcome, Photosensitizing Agents, Angiogenesis Inhibitors, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.